Form 8-K NovoCure Ltd For: Oct 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St set for lower open as bond yields climb; Walmart falls
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy
October 16, 2024 6:06 AM EDTH.C. Wainwright analyst Emily Bodnar upgraded NovoCure Ltd. (NASDAQ: NVCR) from Neutral to Buy with a price target of $30.00.
The analyst comments "Optune Lua receives FDA approval with favorable label based on the LUNAR Phase 3 study. Yesterday after market close, Novocure announced that the FDA has approved Optune Lua for the treatment of metastatic NSCLC for use concurrently with PD-(L)1 inhibitors or docetaxel in patients who have progressed on or after a platinum based regimen. The approval was based on the Phase 3 LUNAR study which demonstrated that there was a 3.3... More
